skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Refinado por: Nome da Publicação: British Journal Of Dermatology remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

The EGALITY study: a confirmatory, randomized, double‐blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate‐to‐severe chronic plaque‐type psoriasis

Griffiths, C.E.M. ; Thaçi, D. ; Gerdes, S. ; Arenberger, P. ; Pulka, G. ; Kingo, K. ; Weglowska, J. ; Hattebuhr, N. ; Poetzl, J. ; Woehling, H. ; Wuerth, G. ; Afonso, M.

British journal of dermatology (1951), 2017-04, Vol.176 (4), p.928-938 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
2
药物 Tildrakizumab 治疗斑块型银屑病的研究
药物 Tildrakizumab 治疗斑块型银屑病的研究
Material Type:
Artigo 		Adicionar ao Meu Espaço

药物 Tildrakizumab 治疗斑块型银屑病的研究

Kimball, A.B. ; Papp, K.A. ; Reich, K. ; Gooderham, M. ; Li, Q. ; Cichanowitz, N. ; La Rosa, C. ; Blauvelt, A.

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.e208-e208 [Periódico revisado por pares]

Oxford: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
3
Etanercept biosimilar SB4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐centre, observational, retrospective, real‐life study
Etanercept biosimilar SB4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐centre, observational, retrospective, real‐life study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Etanercept biosimilar SB4 in the treatment of plaque‐type psoriasis and psoriatic arthritis: a single‐centre, observational, retrospective, real‐life study

Giunta, A. ; Manfreda, V. ; Esposito, M. ; Del Duca, E. ; Bianchi, L.

British journal of dermatology (1951), 2019-11, Vol.181 (5), p.1078-1079 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
4
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Infections from seven clinical trials of ixekizumab, an anti‐interleukin‐17A monoclonal antibody, in patients with moderate‐to‐severe psoriasis

Papp, K.A. ; Bachelez, H. ; Blauvelt, A. ; Winthrop, K.L. ; Romiti, R. ; Ohtsuki, M. ; Acharya, N. ; Braun, D.K. ; Mallbris, L. ; Zhao, F. ; Xu, W. ; Walls, C.D. ; Strober, B.

British journal of dermatology (1951), 2017-12, Vol.177 (6), p.1537-1551 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
5
Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of injection‐site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study

Girolomoni, G. ; Feldman, S.R. ; Emery, P. ; Ghil, J. ; Keum, J.W. ; Cheong, S.Y. ; Hong, E.

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.e215-e216 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
6
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

Papp, K.A. ; Leonardi, C.L. ; Blauvelt, A. ; Reich, K. ; Korman, N.J. ; Ohtsuki, M. ; Paul, C. ; Ball, S. ; Cameron, G.S. ; Erickson, J. ; Zhang, L. ; Mallbris, L. ; Griffiths, C.E.M.

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.674-681 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
7
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)
Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double‐blinded, controlled studies (UNCOVER‐1, UNCOVER‐2, UNCOVER‐3)

Papp, K.A. ; Leonardi, C.L. ; Blauvelt, A. ; Reich, K. ; Korman, N.J. ; Ohtsuki, M. ; Paul, C. ; Ball, S. ; Cameron, G.S. ; Erickson, J. ; Zhang, L. ; Mallbris, L. ; Griffiths, C.E.M.

British journal of dermatology (1951), 2018-03, Vol.178 (3), p.e242-e242 [Periódico revisado por pares]

Oxford: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
8
A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate‐to‐severe chronic plaque‐type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate‐to‐severe chronic plaque‐type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study
Material Type:
Artigo 		Adicionar ao Meu Espaço

A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate‐to‐severe chronic plaque‐type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study

Vries, A.C.Q. ; Thio, H.B. ; Kort, W.J.A. ; Opmeer, B.C. ; Stok, H.M. ; Jong, E.M.G.J. ; Horvath, B. ; Busschbach, J.J.V. ; Nijsten, T.E.C. ; Spuls, Ph.I.

British journal of dermatology (1951), 2017-03, Vol.176 (3), p.624-633 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
9
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies

Kimball, A.B. ; Papp, K.A. ; Reich, K. ; Gooderham, M. ; Li, Q. ; Cichanowitz, N. ; La Rosa, C. ; Blauvelt, A.

British journal of dermatology (1951), 2020-06, Vol.182 (6), p.1359-1368 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis
Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Biologic drug survival rates in the era of anti‐interleukin‐17 antibodies: a time‐period‐adjusted registry analysis

Graier, T. ; Salmhofer, W. ; Jonak, C. ; Weger, W. ; Kölli, C. ; Gruber, B. ; Sator, P.G. ; Prillinger, K. ; Mlynek, A. ; Schütz‐Bergmayr, M. ; Richter, L. ; Ratzinger, G. ; Painsi, C. ; Selhofer, S. ; Häring, N. ; Wippel‐Slupetzky, K. ; Skvara, H. ; Trattner, H. ; Tanew, A. ; Inzinger, M. ; Tatarski, R. ; Bangert, C. ; Ellersdorfer, C. ; Lichem, R. ; Gruber‐Wackernagel, A. ; Hofer, A. ; Legat, F. ; Schmiedberger, E. ; Strohal, R. ; Lange‐Asschenfeldt, B. ; Schmuth, M. ; Vujic, I. ; Hoetzenecker, W. ; Trautinger, F. ; Saxinger, W. ; Müllegger, R. ; Quehenberger, F. ; Wolf, P.

British journal of dermatology (1951), 2021-06, Vol.184 (6), p.1094-1105 [Periódico revisado por pares]

Oxford: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.